Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) CFO Antony A. Riley acquired 22,514 shares of the firm's stock in a transaction dated Thursday, November 21st. The shares were purchased at an average cost of $5.55 per share, for a total transaction of $124,952.70. Following the acquisition, the chief financial officer now directly owns 30,776 shares in the company, valued at $170,806.80. This represents a 272.50 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Forte Biosciences Stock Performance
NASDAQ:FBRX opened at $16.00 on Friday. The stock's 50 day moving average price is $5.91 and its two-hundred day moving average price is $2.69. Forte Biosciences, Inc. has a 12-month low of $4.11 and a 12-month high of $21.25.
Analyst Ratings Changes
Separately, Chardan Capital lifted their price objective on Forte Biosciences from $3.00 to $64.00 and gave the company a "buy" rating in a research report on Friday, November 15th.
Read Our Latest Report on Forte Biosciences
About Forte Biosciences
(
Get Free Report)
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
